Profile
ACHL VRTX REGN VRNA ARGX ALNY
Company Name Achilles Therapeutics plc Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Verona Pharma plc argenx SE Alnylam Pharmaceuticals, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $60.83M $115.36B $77.44B $72.68B $52.08B $51.68B
Employees 0.20K 6.10K 15.16K 0.21K 1.60K 2.23K
CEO Iraj Ali Reshma Kewalramani Leonard S. Schleifer David S. Zaccardelli Timothy Van Hauwermeiren Yvonne L. Greenstreet
Ratings
ACHL VRTX REGN VRNA ARGX ALNY
Quant Rating Score 3 4 4 1 4 3
Quant Rating Neutral Buy Buy Strong Sell Buy Neutral
Trading
ACHL VRTX REGN VRNA ARGX ALNY
Last Close $1.48 $434.02 $704.31 $106.91 $929.61 $460.54
High 52 $1.49 $513.76 $788 $106.91 $929.61 $491.09
Low 52 $0.97 $366.54 $482.92 $37.86 $532.27 $224.58
Price vs. 52 Week High -0.67 % -15.52 % -10.62 % 0 % 0 % -6.22 %
Price vs. 52 Week Low 52.58 % 18.41 % 45.84 % 182.38 % 74.65 % 105.07 %
Total Return
ACHL VRTX REGN VRNA ARGX ALNY
1 Month Return 0 % 4.13 % 21.84 % 0 % 10.19 % -4.39 %
3 Month Return 0 % 11.32 % 22.74 % 1.06 % 40.57 % 0.8 %
6 Month Return 0 % -1.06 % 18.51 % 49.92 % 64.35 % 61.42 %
9 Month Return 6.47 % -6.08 % 3.57 % 66.4 % 45.48 % 84.22 %
YTD Return 29.82 % 7.78 % -1.13 % 130.21 % 51.16 % 95.72 %
1 Year Return 40.95 % -3.12 % -5.41 % 180.68 % 61.8 % 96.59 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ACHL VRTX REGN VRNA ARGX ALNY
Dividend Yield Percentage (TTM) - - 0.47 % - - -
Dividend Paid and Capex Coverage Ration (TTM) -480.78 % 9.76 % 4.25 % -147.93 % 65.28 % 5.97 %
Dividend Per Share (TTM) - - 3.52 % - - -
Payout Ratio (TTM) - - 6.06 % - - -
Profitability
ACHL VRTX REGN VRNA ARGX ALNY
Gross Profit Margin TTM - 86.28 % 85.39 % 95.15 % 65.82 % 83.99 %
Return on Assets TTM -29.33 % 14.78 % 11.4 % -11.01 % 15.06 % 0.9 %
Return on Equity TTM -32.91 % 19.62 % 15.31 % -30.05 % 18.96 % 26.13 %
Return on Capital Employed TTM -36.67 % 19.59 % 10.32 % -8.31 % 5.04 % 8.03 %
Net Income Per EBT TTM 100.01 % 82.61 % 88.98 % 111.64 % 237.3 % -136.38 %
EBT Per Ebit TTM 94.13 % 111.4 % 139.5 % 130.36 % 147.38 % -12.07 %
EBIT Per Revenue TTM - 34.06 % 25.89 % -25.86 % 13.47 % 8.25 %
Cash Flow To Debt Ratio TTM -0.48 % 202.64 % 187.43 % -29.66 % 932.29 % 9.59 %
Receivables Turnover TTM - 6.02 2.51 1.93 1.91 3.33
Payables Turnover TTM 0.28 0.4 2.3 2.37 0.9 4.37
Inventory Turnover TTM - 0.99 0.64 0.94 2.26 6.82
Fixed Asset Turnover TTM - 388.59 % 284.82 % 6536.22 % 5009.77 % 463.12 %
Asset Turnover TTM - 47.15 % 35.47 % 29.27 % 31.97 % 66.16 %
Operating Cash Flow Per Share TTM - 14.55 48.94 -0.85 5.67 2.02
Free Cash Flow Per Share TTM - 13.06 40.09 -0.85 5.58 1.68
Cash Per Share TTM 212.86 % 2459.7 % 8148.65 % 511.43 % 5536.58 % 2072.79 %
Operating Cash Flow Sales Ratio TTM - 31.71 % 35.59 % -43.23 % 17.54 % 8.28 %
Free Cash Flow Operating Cash Flow Ratio TTM 100.21 % 89.76 % 81.92 % 100.75 % 98.47 % 83.26 %
Cash Flow Coverage Ratios TTM -0.48 % 202.64 % 187.43 % -29.66 % 932.29 % 9.59 %
Price To Free Cash Flows Ratio TTM -3507.15 34.57 18.64 -995.27 133.11 233.46
Price To Operating Cash Flows Ratio TTM -3456.91 30.9 15.32 -126.33 152.03 193.4
Price Cash Flow Ratio TTM -3456.91 30.9 15.32 -126.33 152.03 193.4
Income Statement (TTM)
ACHL VRTX REGN VRNA ARGX ALNY
Revenue $0B $11.02B $14.2B $0.03B $2.19B $2.25B
Gross Profit $-0B $9.49B $12.23B $0.03B $1.96B $1.92B
Gross Profit Ratio 0% 86.11% 86.13% 93.89% 89.62% 85.62%
EBITDA $-0.07B $0.49B $5.32B $-0.12B $0.11B $-0.18B
Net Income $-0.07B $-0.54B $4.41B $-0.14B $0.83B $-0.28B
EPS Diluted -1.74 -2.08 38.34 -1.73 12.78 -2.18
Balance Sheet (MRQ)
ACHL VRTX REGN VRNA ARGX ALNY
Long Term Debt $0B $1.66B $2.7B $0.12B $0.03B $2.59B
Total Liabilities $0.02B $6.12B $8.41B $0.27B $0.7B $4.17B
Total Equity $0.14B $16.41B $29.35B $0.2B $5.5B $0.07B
Total Investments $0B $6.65B $15.42B $0.02B $1.93B $1.73B
Total Debt $0B $1.75B $2.7B $0.12B $0.04B $2.74B
Total Assets $0.16B $22.53B $37.76B $0.47B $6.2B $4.24B
Cash Flow Statement (TTM)
ACHL VRTX REGN VRNA ARGX ALNY
Net Income $-0.07B $-0.54B $4.41B $-0.17B $0.83B $-0.28B
Inventory $0B $-0.52B $-0.62B $-0.01B $-0.1B $0.01B
Dividends Paid $0B $0B $0B $0B $0B $0B
Operating Cash Flow $-0.05B $-0.49B $4.42B $-0.12B $-0.08B $-0.01B
Capital Expenditure $-0B $-0.3B $-0.76B $-0B $-0.07B $-0.03B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.05
AAPG 28.9943
AARD Aardvark Therapeutics, Inc. Common Stock 13.415
ABCL AbCellera Biologics Inc. 3.5699
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 4.835
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 2.05
ABPWW 0.014
ABSI Absci Corporation 3.465
ABUS Arbutus Biopharma Corporation 4.615
ABVC ABVC BioPharma, Inc. 2.085
ABVX Abivax SA American Depositary Shares 116.98
ACAD ACADIA Pharmaceuticals Inc. 26.93
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 0.4815
ACGN Aceragen, Inc. 0.3849
ACHV Achieve Life Sciences, Inc. 4.323
ACIU AC Immune SA 3.02
ACLX Arcellx, Inc. 64.95
ETFs With Exposure to ACHL
Ticker ETF Name Weight Percentage Price
IBB iShares Biotechnology ETF 0.01 166.681
BIB ProShares Ultra Nasdaq Biotechnology 0 77.81
IBBQ Invesco Nasdaq Biotechnology ETF 0 28.05
BTEC.L iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) 0.01 8.2257
Unlock